The activity-regulated cytoskeleton-associated protein, Arc/Arg3.1, influences mouse cocaine self-administration.
Animals
Cocaine
/ administration & dosage
Conditioning, Operant
/ drug effects
Cytoskeletal Proteins
/ biosynthesis
Dopamine Uptake Inhibitors
/ administration & dosage
Dose-Response Relationship, Drug
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Nerve Tissue Proteins
/ biosynthesis
Self Administration
Cocaine
Dose-response
Immediate early gene
Intravenous self-administration
Journal
Pharmacology, biochemistry, and behavior
ISSN: 1873-5177
Titre abrégé: Pharmacol Biochem Behav
Pays: United States
ID NLM: 0367050
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
31
10
2018
revised:
01
10
2019
accepted:
30
10
2019
pubmed:
5
11
2019
medline:
1
1
2021
entrez:
5
11
2019
Statut:
ppublish
Résumé
The activity-regulated cytoskeleton-associated protein (Arc, also known as Arg3.1), an immediate early gene and synaptic regulator, is upregulated following a single cocaine exposure. However, there is not much known regarding Arc/Arg3.1's potential contribution to addiction-relevant behaviors. Despite known learning and memory deficits in contextual fear and water-maze reversal learning tasks, we find that mice lacking Arc/Arg3.1 perform conditioned place preference and operant conditioning involving positive reinforcers (food and cocaine) with little-to-no impairment. However, following normal saline-extinction, wild type (WT) mice show a classic inverted-U dose-response function, while Arc/Arg3.1 knockout (KO) mice fail to adjust their intake across multiple doses. Importantly, Arc/Arg3.1 KO and WT mice behave comparably on an increasing cost task (FR1-FR3; acquisition dose), providing evidence that both groups find cocaine reinforcing. Differences in individuals that drive variations in use patterns and particularly, drug intake levels, are critical as they influence the likelihood of developing dependence. Our data suggest that Arc/Arg3.1 may contribute to addiction as a regulator of drug-taking vulnerability under different drug availability conditions.
Identifiants
pubmed: 31682894
pii: S0091-3057(18)30570-7
doi: 10.1016/j.pbb.2019.172818
pmc: PMC7202920
mid: NIHMS1547945
pii:
doi:
Substances chimiques
Cytoskeletal Proteins
0
Dopamine Uptake Inhibitors
0
Nerve Tissue Proteins
0
activity regulated cytoskeletal-associated protein
0
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
172818Subventions
Organisme : NIDA NIH HHS
ID : F32 DA036319
Pays : United States
Organisme : NIDA NIH HHS
ID : R00 DA027825
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA027664
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA032708
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):316-21
pubmed: 19116276
J Vis Exp. 2016 Feb 18;(108):53107
pubmed: 26967472
Synapse. 2008 Jun;62(6):421-31
pubmed: 18361437
Neuron. 2006 Nov 9;52(3):437-44
pubmed: 17088210
Behav Brain Res. 2011 Sep 30;223(1):182-91
pubmed: 21549764
J Neurosci. 2002 Apr 1;22(7):2977-88
pubmed: 11923462
Neuron. 2008 Jul 10;59(1):84-97
pubmed: 18614031
J Neurosci. 2005 Sep 7;25(36):8141-9
pubmed: 16148222
Genes Cells. 2016 Nov;21(11):1263-1269
pubmed: 27659147
Brain Struct Funct. 2008 Sep;213(1-2):215-27
pubmed: 18488248
Curr Protoc Neurosci. 2005 Aug;Chapter 9:Unit 9.20
pubmed: 18428629
Exp Clin Psychopharmacol. 2011 Oct;19(5):321-41
pubmed: 21843010
Cell Rep. 2016 Aug 23;16(8):2116-2128
pubmed: 27524619
J Neural Transm (Vienna). 2012 Jul;119(7):833-42
pubmed: 22622366
J Neural Transm (Vienna). 2011 Jun;118(6):877-87
pubmed: 21318636
Pharmacol Biochem Behav. 1997 Jul;57(3):543-50
pubmed: 9218279
Nat Neurosci. 1999 Dec;2(12):1120-4
pubmed: 10570490
Neuroscience. 2004;125(1):7-11
pubmed: 15051140
Int J Neuropsychopharmacol. 2011 Jul;14(6):784-95
pubmed: 20942997
J Neurochem. 2004 Jun;89(5):1111-8
pubmed: 15147503
J Neurosci. 2012 Apr 25;32(17):5924-36
pubmed: 22539853
Semin Cell Dev Biol. 2018 May;77:17-24
pubmed: 28890421
Science. 1998 Oct 9;282(5387):298-300
pubmed: 9765157
Nat Neurosci. 2007 Aug;10(8):1029-37
pubmed: 17618281
Cell. 2003 Feb 7;112(3):317-27
pubmed: 12581522
Neuron. 2012 Jan 12;73(1):108-20
pubmed: 22243750
Crit Rev Toxicol. 2008;38(7):591-8
pubmed: 18709567
J Neurosci. 2000 Jun 1;20(11):4226-32
pubmed: 10818158
Neuroscience. 2010 Oct 13;170(2):570-9
pubmed: 20654701
Neuron. 2006 Nov 9;52(3):475-84
pubmed: 17088213
Learn Mem. 2003 Mar-Apr;10(2):99-107
pubmed: 12663748
Mol Psychiatry. 2016 Mar;21(3):364-75
pubmed: 25802982
Genes Brain Behav. 2019 Sep;18(7):e12561
pubmed: 30761730
J Neurochem. 1995 May;64(5):2377-80
pubmed: 7722525
Nat Neurosci. 2006 Aug;9(8):1050-6
pubmed: 16829955
Nat Neurosci. 2002 Feb;5(2):169-74
pubmed: 11802171
Biol Psychiatry. 2017 Apr 1;81(7):573-584
pubmed: 27567310
Neuron. 2008 Jul 10;59(1):70-83
pubmed: 18614030
J Neurosci. 2011 May 11;31(19):7073-82
pubmed: 21562269
Int J Neuropsychopharmacol. 2015 Mar 06;18(9):
pubmed: 25746394
Mol Brain. 2014 Apr 23;7:30
pubmed: 24758170
Neuron. 2006 Nov 9;52(3):445-59
pubmed: 17088211
Cell. 2006 Jul 28;126(2):389-402
pubmed: 16873068
Psychopharmacology (Berl). 2016 Feb;233(4):579-89
pubmed: 26554388
J Neurochem. 2013 Jan;124(1):100-8
pubmed: 23113797
Science. 2011 Dec 23;334(6063):1669-75
pubmed: 22194569
J Neurosci. 2000 Jun 1;20(11):3993-4001
pubmed: 10818134
Pharmacol Biochem Behav. 2008 Sep;90(3):349-56
pubmed: 18466961
J Neurosci. 2008 Nov 19;28(47):12383-95
pubmed: 19020031
Schizophr Res. 2016 Oct;176(2-3):106-113
pubmed: 27464451
J Neurosci. 2016 Feb 3;36(5):1723-9
pubmed: 26843652
Int J Neuropsychopharmacol. 2009 Apr;12(3):423-9
pubmed: 19025723
Neuron. 2013 Oct 2;80(1):72-9
pubmed: 24094104
Psychopharmacology (Berl). 2004 Jan;171(3):349-51; author reply 352-63
pubmed: 14530895
PLoS One. 2015 Oct 16;10(10):e0135076
pubmed: 26474411
Psychopharmacology (Berl). 2008 May;198(1):77-91
pubmed: 18311559